Stryker (SYK) Shows ‘Muscle’ at Investor Day, but Truist Stays Neutral

Stryker Corporation (NYSE:SYK) is included among the 15 Blue Chip Dividend Stocks to Build a Passive Income Porfolio.

On November 14, Truist’s analyst Richard Newitter boosted the price target on Stryker Corporation (NYSE:SYK) to $400 from $392 and maintained a Hold rating on the stock. The analyst noted that the company’s Investor Day stressed its position as one of the stronger large-cap MedTech names with ‘muscle’, with the ability to deliver steady operating leverage each year. That said, the firm is maintaining a neutral stance for now, highlighting its preference for companies with steady revenue growth and faster earnings.

In its earnings for the third quarter of 2025, Stryker Corporation (NYSE:SYK)’s management noted the company’s commitment to margin expansion and strong performance despite tariff headwinds. The company’s revenue for the quarter was $6.1 billion, which grew by over 10% from the same period last year. Its organic sales rose by 9.5%, which included 9.1% from increased unit volume and 0.4% from higher prices. The company now expects organic net sales growth of 9.8% to 10.2%.

In addition to strong earnings growth, Stryker Corporation (NYSE:SYK)’s 32-year dividend growth streak is also appealing to income investors. Moreover, the payout ratio of around 43% indicated future dividend growth.

Stryker Corporation (NYSE:SYK) is a medical technology company that manufactures and markets a wide range of products and services.

READ NEXT: 15 High Quality Dividend Stocks for Long-Term Investors and 15 Dividend Stocks That Outperform the S&P 500

Disclosure: None.